Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:19 pm Purchase | 2025-09-30 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 1,181,194 9.990% | 13,077 (+1.12%) | Filing History |
| 2025-11-13 5:31 pm Purchase | 2025-09-30 | 13G | Palvella Therapeutics, Inc. PVLA | SUVRETTA CAPITAL MANAGEMENT, LLC | 822,400 7.400% | 107,937 (+15.11%) | Filing History |
| 2025-08-14 5:26 pm Sale | 2025-06-30 | 13G | Palvella Therapeutics, Inc. PVLA | Samsara BioCapital, L.P. | 339,743 3.100% | -339,743 (-50.00%) | Filing History |
| 2025-08-14 1:41 pm Sale | 2025-06-30 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 545,504 4.900% | -144,508 (-20.94%) | Filing History |
| 2025-05-15 09:39 am Purchase | 2025-03-31 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 690,012 6.300% | 114,120 (+19.82%) | Filing History |
| 2025-01-08 3:04 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 575,892 5.100% | 575,892 (New Position) | Filing History |
| 2024-12-20 5:32 pm Purchase | 2024-12-13 | 13D | Palvella Therapeutics, Inc. PVLA | Kaupinen Wes | 1,644,869 14.600% | 1,644,869 (New Position) | Filing History |
| 2024-12-20 4:59 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | Samsara BioCapital, L.P. | 679,486 6.100% | 679,486 (New Position) | Filing History |
| 2024-12-20 4:56 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | SUVRETTA CAPITAL MANAGEMENT, LLC | 714,463 8.600% | 714,463 (New Position) | Filing History |
| 2024-12-17 5:42 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 1,168,117 9.990% | 1,168,117 (New Position) | Filing History |
| 2024-12-17 4:22 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | Dellora Investments Master Fund LP | 141,079 1.300% | 141,079 (New Position) | Filing History |
| 2024-12-06 2:21 pm Purchase | 2024-11-06 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Dellora Investments Master Fund LP | 141,079 10.700% | 32,105 (+29.46%) | Filing History |
| 2024-11-14 09:07 am Sale | 2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS | LYNX1 CAPITAL MANAGEMENT LP | 37,436 2.800% | -84,762 (-69.36%) | Filing History |
| 2024-08-07 2:16 pm Purchase | 2024-07-24 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Dellora Investments Master Fund LP | 108,974 8.300% | 108,974 (New Position) | Filing History |
| 2024-08-01 08:00 am Purchase | 2024-07-24 | 13G | Pieris Pharmaceuticals, Inc. PIRS | ADAR1 Capital Management, LLC | 138,641 10.500% | 138,641 (New Position) | Filing History |
| 2024-05-17 5:07 pm Unchanged | 2024-05-15 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,622 19.500% | 0 (Unchanged) | Filing History |
| 2024-05-17 5:07 pm Purchase | 2024-05-15 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,622 19.500% | 257,622 (New Position) | Filing History |
| 2024-02-14 4:37 pm Sale | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Aquilo Capital Management LLC | 14,085 1.100% | -56,911 (-80.16%) | Filing History |
| 2024-02-14 1:12 pm Sale | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Checkpoint Capital L.P. | 0 0.000% | -61,731 (Position Closed) | Filing History |
| 2024-02-14 09:19 am Purchase | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | LYNX1 CAPITAL MANAGEMENT LP | 122,198 9.900% | 51,841 (+73.68%) | Filing History |